Limits...
Effect of targeted ovarian cancer therapy using amniotic fluid mesenchymal stem cells transfected with enhanced green fluorescent protein-human interleukin-2 in vivo.

You Q, Yao Y, Zhang Y, Fu S, Du M, Zhang G - Mol Med Rep (2015)

Bottom Line: The aim of the present study was to investigate the effect of using amniotic fluid mesenchymal stem cells (AF-MSCs) in targeted ovarian cancer therapy in vivo.AF-MSCs were isolated from human second trimester AF and a plasmid, enhanced green fluorescent protein‑human interleukin‑2 (pEGFP‑hIL‑2) was formed.It was found that AF‑MSCs exhibited high motility during migration in vivo, and the vector, pEGFP‑hIL‑2 can be stably transfected into AF‑MSCs.

View Article: PubMed Central - PubMed

Affiliation: Department of Gynecology and Obstetrics, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China.

ABSTRACT
The aim of the present study was to investigate the effect of using amniotic fluid mesenchymal stem cells (AF-MSCs) in targeted ovarian cancer therapy in vivo. AF-MSCs were isolated from human second trimester AF and a plasmid, enhanced green fluorescent protein‑human interleukin‑2 (pEGFP‑hIL‑2) was formed. The plasmid was stably transfected into the AF‑MSCs and the cells were intravenously injected into ovarian cancer nude mice models. Following stable transfection of the vector, tumor formation, and the expression and activity of hIL‑2 were investigated, and microscopic pathological examinations of the tumor were performed. It was found that AF‑MSCs exhibited high motility during migration in vivo, and the vector, pEGFP‑hIL‑2 can be stably transfected into AF‑MSCs. Following stable transfection, this type of stem cell is able to successfully transport the therapeutic gene, IL-2, migrate to the ovarian cancer tumor site to secrete the functional IL-2 and treat the tumor. Thus, AF-MSCs may serve as transporters for therapeutic genes targeting ovarian tumor sites and, therefore, be involved in the treatment of tumors.

Show MeSH

Related in: MedlinePlus

Enhanced green fluorescent protein-transfected amniotic fluid mesenchymal stem cells express OCT4. Lane 1, negative control; lane 2, positive control; lane 3, OCT4 mRNA; lane 4, marker. OCT4, octamer-binding protein 4.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4581758&req=5

f5-mmr-12-04-4859: Enhanced green fluorescent protein-transfected amniotic fluid mesenchymal stem cells express OCT4. Lane 1, negative control; lane 2, positive control; lane 3, OCT4 mRNA; lane 4, marker. OCT4, octamer-binding protein 4.

Mentions: Human AF-MSCs were successfully isolated from second trimester AF (Fig. 3) and the EGFP gene was transfected into the AF-MSCs via lipofection (Fig. 4; EGFP gene transfection efficiency, 30%). The EGFP-transfected AF-MSCs were found to express OCT4 (Fig. 5). Furthermore, EGFP was expressed in all of the transgenic cells (following selection of the stably transfected cell lines) and could be readily visualized; this expression was maintained over ten passages. The growth curve of the EGFP-transfected AF-MSCs exhibited almost the same characteristics as untransfected AF-MSCs. From day three, the cells entered the logarithmic growth stage and the growth peak was observed on day seven. The doubling time was 30.5 h. No significant difference was identified between the different passages (Fig. 6).


Effect of targeted ovarian cancer therapy using amniotic fluid mesenchymal stem cells transfected with enhanced green fluorescent protein-human interleukin-2 in vivo.

You Q, Yao Y, Zhang Y, Fu S, Du M, Zhang G - Mol Med Rep (2015)

Enhanced green fluorescent protein-transfected amniotic fluid mesenchymal stem cells express OCT4. Lane 1, negative control; lane 2, positive control; lane 3, OCT4 mRNA; lane 4, marker. OCT4, octamer-binding protein 4.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4581758&req=5

f5-mmr-12-04-4859: Enhanced green fluorescent protein-transfected amniotic fluid mesenchymal stem cells express OCT4. Lane 1, negative control; lane 2, positive control; lane 3, OCT4 mRNA; lane 4, marker. OCT4, octamer-binding protein 4.
Mentions: Human AF-MSCs were successfully isolated from second trimester AF (Fig. 3) and the EGFP gene was transfected into the AF-MSCs via lipofection (Fig. 4; EGFP gene transfection efficiency, 30%). The EGFP-transfected AF-MSCs were found to express OCT4 (Fig. 5). Furthermore, EGFP was expressed in all of the transgenic cells (following selection of the stably transfected cell lines) and could be readily visualized; this expression was maintained over ten passages. The growth curve of the EGFP-transfected AF-MSCs exhibited almost the same characteristics as untransfected AF-MSCs. From day three, the cells entered the logarithmic growth stage and the growth peak was observed on day seven. The doubling time was 30.5 h. No significant difference was identified between the different passages (Fig. 6).

Bottom Line: The aim of the present study was to investigate the effect of using amniotic fluid mesenchymal stem cells (AF-MSCs) in targeted ovarian cancer therapy in vivo.AF-MSCs were isolated from human second trimester AF and a plasmid, enhanced green fluorescent protein‑human interleukin‑2 (pEGFP‑hIL‑2) was formed.It was found that AF‑MSCs exhibited high motility during migration in vivo, and the vector, pEGFP‑hIL‑2 can be stably transfected into AF‑MSCs.

View Article: PubMed Central - PubMed

Affiliation: Department of Gynecology and Obstetrics, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China.

ABSTRACT
The aim of the present study was to investigate the effect of using amniotic fluid mesenchymal stem cells (AF-MSCs) in targeted ovarian cancer therapy in vivo. AF-MSCs were isolated from human second trimester AF and a plasmid, enhanced green fluorescent protein‑human interleukin‑2 (pEGFP‑hIL‑2) was formed. The plasmid was stably transfected into the AF‑MSCs and the cells were intravenously injected into ovarian cancer nude mice models. Following stable transfection of the vector, tumor formation, and the expression and activity of hIL‑2 were investigated, and microscopic pathological examinations of the tumor were performed. It was found that AF‑MSCs exhibited high motility during migration in vivo, and the vector, pEGFP‑hIL‑2 can be stably transfected into AF‑MSCs. Following stable transfection, this type of stem cell is able to successfully transport the therapeutic gene, IL-2, migrate to the ovarian cancer tumor site to secrete the functional IL-2 and treat the tumor. Thus, AF-MSCs may serve as transporters for therapeutic genes targeting ovarian tumor sites and, therefore, be involved in the treatment of tumors.

Show MeSH
Related in: MedlinePlus